Search / Trial NCT00000199

Piracetam for Treatment of Cocaine Addiction, Phase II - 4

Launched by UNIVERSITY OF PENNSYLVANIA · Sep 20, 1999

Trial Information

Current as of December 09, 2024

Withdrawn

Keywords

Cocaine

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Please contact site for information.

Trial Officials

Kyle Kampman, M.D.

Principal Investigator

University of Pennsylvania

About University Of Pennsylvania

The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.

Locations

Philadelphia, Pennsylvania, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials